Strides Pharma Science Limited (STAR.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+636.4%

₹7,741.78

vs ₹1,051.30 price

Levered DCF

₹5,693.68

After debt service

Piotroski score

5 / 9

Average

Altman Z-score

2.61

Grey zone

Rating

A-

Overall 4 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	15.54×	15.14×	-29.19×	-5.6×	-3.24×	14.28×	57.27×	39.14×
P/B	2.78×	2.4×	1.65×	0.56×	0.63×	1.31×	0.55×	0.77×
P/S	1.78×	1.37×	0.92×	0.34×	0.49×	1.11×	0.52×	0.97×
EV / EBITDA	9.71×	8.49×	15.19×	18.17×	-17.9×	11.23×	9.13×	19.08×
Gross margin	36.4%	26.4%	22.2%	21.9%	13.4%	29.2%	26.5%	20.1%
Operating margin	14.9%	11.6%	7.9%	3.4%	-8.2%	9.6%	7.0%	4.0%
Net margin	11.4%	9.1%	-3.1%	-6.0%	-15.0%	7.8%	0.9%	2.5%
Current ratio	1.25×	1.2×	1.03×	1.08×	0.99×	1.03×	0.93×	1.13×
Debt / equity	0.57×	0.74×	1.18×	1.37×	1.28×	0.85×	0.88×	1.22×
Interest coverage	4.05×	2.08×	1.08×	0.47×	-1.43×	2.1×	1.21×	1.08×
Dividend yield	0.4%	0.4%	0.4%	0.0%	1.5%	0.5%	11.1%	0.9%
Payout ratio	6.6%	5.7%	-11.2%	0.0%	-4.9%	7.0%	637.3%	34.3%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	17.9%	15.9%	-5.7%	-10.0%	-19.5%	9.2%	1.0%	2.0%
Return on invested capital	12.0%	9.2%	6.4%	1.9%	-3.3%	5.0%	3.0%	1.3%
Return on assets	8.0%	6.7%	-2.1%	-3.3%	-6.6%	3.6%	0.4%	0.7%
Free cash flow yield	1.4%	7.2%	16.6%	-4.1%	-26.9%	5.1%	4.0%	-13.1%
Earnings yield	6.4%	6.6%	-3.4%	-17.9%	-30.8%	7.0%	1.7%	2.6%
Enterprise value	₹101.9B	₹78.8B	₹58.6B	₹39.6B	₹43.5B	₹58.6B	₹34.4B	₹49.1B
Net debt / EBITDA	1.47×	1.88×	6.1×	12.5×	-11.75×	4.26×	5.45×	11.13×
Cash conversion cycle (days)	136	125	143	161	229	138	-3	-5